Intra-Cellular Therapies (ITCI) Tops Q2 EPS by 14c, Raises FY Sales Guidance for CAPLYTA

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Intra-Cellular Therapies (ITCI) Tops Q2 EPS by 14c, Raises FY Sales Guidance for CAPLYTA

Intra-Cellular Therapies Reports Second Quarter 2023 Financial Results and Raises 2023 CAPLYTA Sales Guidance

August 3, 2023 7:30 AM EDT

Q2 2023 total revenues increased to $110.8 million, compared to $55.6 million in the same period in 2022

CAPLYTA Q2 2023 net product sales were $110.1 million, compared to $55.1 million for the same period in 2022, representing a 100% increase

CAPLYTAs strong prescription uptake continues: Q2 2023 CAPLYTA total prescriptions increased 96%, versus the same period in 2022 and 13% sequentially versus Q1 2023

2023 CAPLYTA net product sales guidance raised to $445 - $465 million

NEW YORK, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for... More